Press releases

Isconova AB announces that its partner, VetBioChem, has launched two new dog and cat rabies vaccines on the Russian market. Both vaccines contain Isconova’s Matrix-M™ Vet adjuvant, and Isconova will receive production revenues and royalties on sales.

Isconova AB, a leading international vaccine adjuvant company, is pleased to note that the scientific journal Vaccine has published online, the first article presenting data from the human PanFluVac trial. The phase I clinical study evaluated the safety and the immunogenicity of an avian flu vaccine adjuvanted with Matrix M™. Isconovas Matrix M™ showed excellent results in the study.

Isconova AB, a leading international vaccine adjuvant company and Genocea Biosciences, Inc., a vaccine discovery and development company pioneering a new class of T cell‐based vaccines, today announced the expansion of their collaboration granting Genocea the right to use Isconova’s Matrix M™ in vaccines targeting two additional diseases.

Isconova has appointed Russell Greig, currently a member of its board, as acting CEO for the company. He will assume this position on October 1st 2011 to replace Lena Söderström, who will leave Isconova at the end of September. The recruitment process to find a permanent CEO has been initiated.

Isconova has entered into a new license agreement with Crucell N.V.. The agreement grants Crucell the license to use Isconova’s adjuvant Matrix M™ in HIV and malaria vaccines. An existing agreement between Isconova and Crucell already granted Crucell the right to use Isconova’s Matrix M™ in influenza vaccines.

Isconova moves forward with the clinical Phase I study of seasonal influenza by initiating vaccinations of the first study participants. A total of 110 healthy volunteers will take part in the study, scheduled to be reported during the first quarter of 2012. The study is a result of Isconova’s increased focus on human vaccines.

Isconova AB held its Annual General Meeting on May 5th in Uppsala. The Parent Company and Group’s income statements and balance sheets for the fiscal year 2010 were approved at the meeting. The Board of Directors and CEO were granted a discharge from liability for the fiscal year 2010.

Isconova acquires the assets of Nordic Vaccine A/S, a Danish research and development company specialised in adjuvants and drug delivery development. The acquisition will significantly strengthen Isconova’s patent position within vaccine systems and adjuvant technology.

The Annual General Meeting (AGM) of Isconova AB (publ), corp. reg. no. 556549-4019, will be held at 5.00 p.m. on Thursday, May 5, 2011 at the company’s premises on Kungsgatan 109 in Uppsala, Sweden.

Based on positive results from the clinical Phase I study with Matrix M™ when vaccinating against avian influenza, which was performed in 2009, Isconova has decided to independently conduct a clinical Phase I study of seasonal influenza. The study is a result of Isconova’s increased commitment to human vaccines and is scheduled to start in May 2011.

Isconova’s partner NPO Narvac (”Narvac”) has submitted a registration application in Russia for Matrix M™ based rabies vaccines for dog and cat. Launch of the products on the Russian market is expected end of 2011 after which Isconova independently will prepare for launch on additional markets.

Isconova and Norwegian PHARMAQ AS (“PHARMAQ”) will extend their cooperation after receiving positive notice from Eurostars™ (“Eurostars”) regarding funding of an extensive development project for new, effective, salmon vaccines. Eurostars will finance a large part of Isconova’s and PHARMAQ’s development costs in developing a new, innovative generation of fish vaccines.

Isconova has been selected as a partner in a new EU project. One of the objectives for the project – the so-called WINGS project – is to develop a new vaccine against the viral disease West Nile Fever. Isconova will lead part of the project aimed at optimizing a protein-based vaccine using Isconova’s adjuvant Matrix M™, as well as contribute with its expertise in adjuvants.

This press release may not be released, published or distributed in the U.S., Canada, Australia, Japan or any other country if it requires any additional prospectus prepared or registration or other measures in addition to those required under Swedish law.

Isconova has entered a global, strategic collaboration with Jenner Institute – one of the leading vaccine institutes in the world. The aim of the collaboration is to develop vaccines, including a malaria vaccine, by using Isconova’s knowledge and products.

Isconova initiates collaboration with NPO Narvac (”Narvac”) – one of Russia’s leading companies within veterinary medicine. Initially, the aim is to develop a rabies vaccine for dog and cat for the Russian market. Isconova will own all clinical data and in addition own the commercial rights for the vaccines throughout the rest of the world, except for China, where Isconova and Narvac will co-operate through a joint venture.

Isconova’s adjuvant Matrix M™ has been selected by the Swiss biotech-company Evolva Holding SA (“Evolva”) as one of three immune-stimulating substances further studies (pre-IND). The properties of the product have made it appropriate for use against bio-terrorism.

Pharmaceutical company Isconova has recruited Erik Bergman as CFO. Most recently Erik comes from Orexo’s subsidiary Kibion where he has been CEO since 2009. The recruitment is a step in Isconova’s further expansion, and increased involvement, in the area of human vaccines, concurrent with the Board of Directors’ decision to prepare the company for listing at Nasdaq OMX First North.

Uppsala Sweden August 24, 2009. Isconova AB, a Company developing producing and selling adjuvants for veterinary and human vaccines has appointed a new CEO, Lena Söderström, who will succeed Bengt Falk on 1 November 2009.

Two cornerstone patent applications covering Isconova’s most recent development of its adjuvant technology platform with improved safety and efficacy has been granted in Europe.